Related Experiment Videos
Flunarizine in the treatment of vestibular vertigo: experimental and clinical data
1Medical Department, Janssen GmbH, Neuss, Germany.
Abstract:
Because maintenance antivertiginous treatment with commonly used drugs is only moderately effective, there is still need for new therapeutic concepts in the therapy of vestibular vertigo. The cerebral calcium antagonist flunarizine (Sibelium) revealed positive vestibular effects in experimental animal studies and in healthy volunteers. Clinical trials versus placebo and reference drugs proved flunarizine to be effective in the treatment of vestibular disorders. Somnolence, weight gain, and, in rare cases, extrapyramidal symptoms and depression were discussed as side effects. Further studies on flunarizine's mechanism of action are needed to elucidate whether its clinical effects are indeed due to calcium-entry blockade.
Insights
Flunarizine, a cerebral calcium antagonist, shows effectiveness in treating vestibular vertigo. Further research is needed to confirm its mechanism of action for vertigo treatment.
Area of Science:
- Neurology
- Pharmacology
Background:
- Current antivertiginous treatments offer moderate efficacy for vestibular vertigo.
- There is a need for novel therapeutic strategies to manage vestibular disorders.
Purpose of the Study:
- To evaluate the efficacy of flunarizine as a treatment for vestibular vertigo.
- To explore the therapeutic potential of flunarizine in managing vestibular disorders.
Main Methods:
- Clinical trials comparing flunarizine against placebo and reference medications.
- Preclinical studies in animal models and trials in healthy volunteers to assess vestibular effects.
Main Results:
- Flunarizine demonstrated positive vestibular effects in preclinical and volunteer studies.
- Clinical trials confirmed flunarizine's effectiveness in treating vestibular disorders compared to placebo and reference drugs.
Conclusions:
- Flunarizine is an effective therapeutic option for vestibular vertigo.
- Potential side effects include somnolence, weight gain, and rare extrapyramidal symptoms or depression.
- Further investigation into flunarizine's mechanism of action, specifically calcium-entry blockade, is warranted.